Drug Profile
Tinengotinib - TransThera Biosciences
Alternative Names: TT 00420Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator TransThera Biosciences
- Class 3-ring heterocyclic compounds; Antineoplastics; Chlorobenzenes; Morpholines; Pyrazoles; Pyridones; Small molecules
- Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cholangiocarcinoma
- Phase I/II Solid tumours
- No development reported Triple negative breast cancer
Most Recent Events
- 22 Apr 2024 TransThera Sciences initiates an expanded-access programme for Solid tumour (Late-stage disease, Monotherapy) in USA (PO) (NCT06370013)
- 08 Mar 2024 The regulatory agencies authorizes a phase III FIRST-308 trial in Cholangiocarcinoma in the EU
- 08 Mar 2024 Tinengotinib - TransThera Biosciences receives Orphan Drug status for Biliary cancer in European Union